FOLH1 and prostate cancer: In contrast, it is expressed at low levels in normal tissues such as kidneys, salivary glands, and small intestine (He et al. 2022); thus, PSMA-targeted radioligand therapy (PRLT) has become a popular therapy for the treatment of prostate cancer (Cimadamore et al. 2018; Wang et al. 2022, 2023).